--------------------------------------------------------------------------
This is the foremost premise for our 'Sell' recommendation on the stock. Investors should note we are positive about the company's low risk exports strategy of supplying bulk drugs to generic majors in the regulated markets in the long term, especially considering the potential in terms of large patent expiries in the coming few years. We have accordingly factored the same in our assumptions. Having said that, despite factoring in all the positives, at current valuations, we believe that the risk-reward equation is skewed towards risks and hence the 'Sell' recommendation.
--------------------------------------------------------------------------
The above are EM recommendation.
can be relevant?advice please.
This is the foremost premise for our 'Sell' recommendation on the stock. Investors should note we are positive about the company's low risk exports strategy of supplying bulk drugs to generic majors in the regulated markets in the long term, especially considering the potential in terms of large patent expiries in the coming few years. We have accordingly factored the same in our assumptions. Having said that, despite factoring in all the positives, at current valuations, we believe that the risk-reward equation is skewed towards risks and hence the 'Sell' recommendation.
--------------------------------------------------------------------------
The above are EM recommendation.
can be relevant?advice please.